Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Pircher, M; Mlineritsch, B; Fridrik, MA; Dittrich, C; Lang, A; Petru, E; Weltermann, A; Thaler, J; Hufnagl, C; Gampenrieder, SP; Rinnerthaler, G; Ressler, S; Ulmer, H; Greil, R.
Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial.
Anticancer Res. 2015; 35(1):517-21
Web of Science
PubMed
- Co-Autor*innen der Med Uni Graz
- Petru Edgar
- Rinnerthaler Gabriel
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Abstract:
- BACKGROUND: Trastuzumab, one important treatment option for HER2-positive metastatic breast cancer (MBC) is limited by its cardiotoxic potential. Lapatinib and pegylated liposomal doxorubicin (PLD) represent a cardiosparing alternative that can cross the blood brain barrier. This is important, because one third of breast cancer patients develop brain metastases. PATIENTS AND METHODS: We included 24 patients with HER2-positive MBC progressing under trastuzumab. They received 1,250 mg lapatinib daily until progression plus PLD (40 mg/m(2)) every 4 weeks for maximal 6 cycles. The primary end-point was the overall response rate (ORR). Secondary end-points were progression-free survival (PFS), overall survival (OS), 1-year PFS and 1-year OS rates. RESULTS: ORR was 54%. Median PFS was 5.8 and median OS 23.3 months. The one-year PFS rate was 27% and 1-year OS rate 76%. CONCLUSION: Lapatinib-plus-PLD is active and safe in HER2-positive MBC, especially suitable for patients with cardiological risk or brain metastases.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult - administration & dosage
- Aged - administration & dosage
- Antibodies, Monoclonal, Humanized - administration & dosage, pharmacology
- Antineoplastic Combined Chemotherapy Protocols - therapeutic use
- Brain Neoplasms - drug therapy, metabolism, mortality, secondary
- Breast Neoplasms - drug therapy, metabolism, mortality, pathology
- Disease-Free Survival - administration & dosage
- Doxorubicin - administration & dosage, analogs & derivatives
- Drug Resistance, Neoplasm - administration & dosage
- Female - administration & dosage
- Humans - administration & dosage
- Kaplan-Meier Estimate - administration & dosage
- Lapatinib - administration & dosage
- Middle Aged - administration & dosage
- Polyethylene Glycols - administration & dosage
- Quinazolines - administration & dosage
- Receptor, ErbB-2 - metabolism
- Trastuzumab - administration & dosage
- Treatment Outcome - administration & dosage
- Find related publications in this database (Keywords)
- Metastatic breast cancer
- Her2-positive
- lapatinib
- pegylated liposomal doxorubicin